Development of the EXACT-U: A preference-based measure to report COPD exacerbation utilities

Value in Health

Volumn 14, Issue 4, 2011, Pages 546-554

  Petrillo, Jennifer ^a   Cairns, John ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Chronic bronchitis; Condition specific; COPD; Emphysema; Preference; Time trade off; Utility

Indexed keywords

ADULT; ALGORITHM; ARTICLE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT TOOL; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; EMPHYSEMA; FEMALE; HEALTH STATUS; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; VALIDATION PROCESS;

EID: 79959980439     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2010.10.032     Document Type: Article

References (57)

1. Brazier J, Deverill M, Green C, et al. A review of the use of health status measures in economic evaluation. Health Technol Assess 1999;3:iii- 163. (Pubitemid 29289989)
2. National Institute for Clinical Excellence. Technical guidance for manufacturers and sponsors on making a submission to a technology appraisal. UK, 2008.
3. Haywood KL, Garratt AM, Lall R, et al. EuroQol EQ-5D and conditionspecific measures of health outcome in women with urinary incontinence: reliability, validity and responsiveness. Qual Life Res 2008;17:475-83.
4. Espallargues M, Czoski-Murray CJ, Bansback NJ, et al. The impact of age-related macular degeneration on health status utility values. Investigative Invest Ophthalmol Vis Sci 2005;46:4016-23. (Pubitemid 44264600)
5. Tandon PK, Stander H, Schwarz RP Jr. Analysis of quality of life data from a randomized, placebo-controlled heart-failure trial. J Clin Epidemiol 1989;42:955-62. (Pubitemid 19269620)
6. Paterson C, Langan CE, McKaig GA, et al. Assessing patient outcomes in acute exacerbations of chronic bronchitis: the measure your medical outcome profile (MYMOP), medical outcomes study 6-item general health survey (MOS-6A) and EuroQol (EQ-5D). Qual Life Res 2000;9:521-7. (Pubitemid 32009862)
7. Menn P, Weber N, Holle R. Health-related quality of life in patients with severe COPD hospitalized for exacerbations-comparing EQ-5D, SF-12 and SGRQ. Health Qual Life Outcomes 2010;8: 39.
8. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997;155:1283-9. (Pubitemid 27172772)
9. Bourbeau J, Ford G, Zackon H, et al. Impact on patients' health status following early identification of a COPD exacerbation. Eur Respir J 2007;30:907-13. (Pubitemid 351194794)
10. O'Reilly, JF, Williams AE, and Rice L. Health status impairment and costs associated with COPD exacerbation managed in hospital. Int J Clin Pract 2007;61:1112-20. (Pubitemid 46934632)
11. Chiou CF, Weaver MR, Bell MA, et al. Development of the multiattribute pediatric asthma health outcome measure (PAHOM). Int J Qual Health Care 2005;17:23-30. (Pubitemid 40260140)
12. Revicki DA, Leidy NK, Brennan-Diemer F, et al. Integrating patient preferences into health outcomes assessment: the multiattribute asthma symptom utility index. Chest 1998;114:998-1007. (Pubitemid 28495893)
13. Brazier J, Usherwood T, Harper R, et al. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol 1998; 51:1115-28. (Pubitemid 28527167)
14. Brazier JR, Salomon J, Tsuchiya A. Measuring and Valuing Health Benefits for Economic Evaluation. Oxford: Oxford University Press, 2007.
15. McKenna SP, Ratcliffe J, Meads DM, et al. Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses. Health Qual Life Outcomes 2008;6:65.
16. Young T, Yang Y, Brazier JE, et al. The first stage of developing preference-based measures: constructing a health-state classification using Rasch analysis. Qual Life Res 2009;18:253-65.
17. National Institute for Health and Clinical Excellence (NICE). Technical guidance for manufacturers and sponsors on making a submission to a technology appraisal. London: 2008.
18. Yang Y, Brazier J, Tsuchiya A, et al. Estimating a preference-based single index from the overactive bladder questionnaire. Value Health 2009;12:159-66.
19. Leidy NK, Powers JH, Howard KA, et al. The EXACT-PRO Initiative: development of a standardized outcome measure for evaluating exacerbations of chronic obstructive pulmonary disease. American Thoracic Society International Conference. Toronto, Ontario, Canada, 2008.
20. Leidy NK, Wilcox TK, Jones PW, et al. Development of the exacerbations of chronic obstructive pulmonary disease tool (EXACT): a patient-reported outcome (PRO) measure. Value Health 2010, DOI: VHE772 [pii]10.1111/j.1524-4733.2010. 00772.x.
21. Aaron SD, Vandemheen KL, Clinch JJ, et al. Measurement of shortterm changes in dyspnea and disease-specific quality of life following an acute COPD exacerbation. Chest 2002;121:688-96. (Pubitemid 34251429)
22. Leidy NK, Wilcox T, Roberts, L, Winnette RM, Murray L. The EXACTPRO Initiative: development and validation of a single patientreported outcome measure for evaluating exacerbations of chronic obstructive pulmonary disease. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 11th Annual European Meeting. Athens, Greece, 2008.
23. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92. (Pubitemid 34143147)
24. Marx RG, Bombardier C, Hogg-Johnson S, et al. Clinimetric and psychometric strategies for development of a health measurement scale. J Clin Epidemiol 1999;52:105-11. (Pubitemid 29118359)
25. Bond TG, Fox CM. Applying the Rasch Model: Fundamental Measurement in the Human Sciences. Mahwah NJ: Lawrence Erlbaum Assoc, 2001.
26. Petrillo J, Cairns J, Lamping DL, Jones PW. Item Identification for the EXACT-U: A Preference-based Measure to Report Utilities for COPD Exacerbations. International Society for Quality of Life Research. London: 2010.
27. Stevens K, McCabe C, Brazier J, et al. Multi-attribute utility function or statistical inference models: a comparison of health state valuation models using the HUI2 health state classification system. J Health Econ 2007;26:992-1002. (Pubitemid 47239111)
28. Chancellor JVM, Coyle D, Drummond MF. Constructing health state preference values from descriptive quality of life outcomes: mission impossible? Qual Life Res 1997;6:159-68. (Pubitemid 27207281)
29. MVH Group. The Measurement and Valuation of Health. Final report on the modelling of valuation tariffs. York, UK: York Centre for Health Economics, 1995.
30. Kind P. The EuroQoL instrument: an index of health-related quality of life. In: Spilker B, ed., Quality of Life and Pharmacoeconomics in Clinical Trials (2nd Ed.). Philadelphia: Lippincott-Raven Publishers, 1996.
31. Dolan P, Gudex C, Kind P, et al. Valuing health states: a comparison of methods. J Health Econ 1996;15:209-31. (Pubitemid 26290919)
32. Dolan P, Gudex C, Kind P, et al. The time trade-off method: results from a general population study. Health Econ 1996;5:141-54. (Pubitemid 126484860)
33. King JT Jr, Styn MA, Tsevat J, et al. "Perfect health" versus "disease free": the impact of anchor point choice on the measurement of preferences and the calculation of disease-specific disutilities. Med Decis Making 2003;23:212-25. (Pubitemid 36618062)
34. Devlin NJ, Parkin D, Browne J. Patient-reported outcome measures in the NHS: new methods for analysing and reporting EQ-5D data. Health Econ 2010;19:886-905.
35. Stalmeier PFM, Buusschbach JJV, Lamers LM, et al. The gap effect: discontinuities of preferences around dead. Health Econ 2005;14:679-85. (Pubitemid 40960224)
36. Torrance GW, Feeny DH, Furlong WJ, et al. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Med Care 1996;34:702-22. (Pubitemid 126433265)
37. Lamers LM, Stalmeier PFM, Krabbe PFM, et al. Inconsistencies in TTO and VAS values for EQ-5D health states. Med Decis Making 2006;26: 173-81.
38. StataCorp L. STATA 10. 2007.
39. Dolan P. Modelling valuation for Euroqol health states. Med Care. 1997;35:351-63.
40. Hardin JH. Generalized Linear Models and Extensions (2nd ed.). College Station, Texas: Stata Press, 2007.
41. Stock JW. M Introduction to Econometrics (2nd ed.). Boston, MA: Addison-Wesley, 2003.
42. Brazier J, Czoski-Murray C, Roberts J, et al. Estimation of a preferencebased index from a condition-specific measure: The King's health questionnaire. Med Decis Making 2008;28:113-26.
43. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108. (Pubitemid 127453463)
44. Wright DR, Wittenberg E, Swan JS, et al. Methods for measuring temporary health states for cost-utility analyses. Pharmacoeconomics 2009;27:713-23.
45. Haughney J, Gruffydd-Jones K. Patient-centred outcomes in primary care management of COPD-What do recent clinical trial data tell us? Prim Care Respir J. 2004;13:185-97. (Pubitemid 39536035)
46. Stavem K. Reliability, validity and responsiveness of two multiattribute utility measures in patients with chronic obstructive pulmonary disease. Qual Life Res 1999;8:45-54. (Pubitemid 29362745)
47. Harper R, Brazier JE, Waterhouse JC, et al. Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting. Thorax 1997;52:879-87. (Pubitemid 27473930)
48. Brown G, Austin J, McGowan I, et al. Is the EuroQol generic health status questionnaire sensitive to the impact of pulmonary rehabilitation in COPD? Am J Respir Crit Care Med 2009;179:A3852.
49. Ringbaek T, Brondum E, Martinez G, et al. EuroQoL in assessment of the effect of pulmonary rehabilitation COPD patients. Respir Med 2008;102:1563-7.
50. Borg S, Ericsson A, Wedzicha J, et al. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health 2004;7:153-67. (Pubitemid 38420728)
51. Sin DD, Golmohammadi K, Jacobs P. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am J Med 2004;116:325-31. (Pubitemid 38230292)
52. Oostenbrink JB, Rutten-van Molken MP, Monz BU, et al. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health. 2005;8: 32-46 (Pubitemid 40293639)
53. Spencer M, Briggs AH, Grossman RF, et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 2005;23:619-37. (Pubitemid 40994129)
54. Rutten-van Molken MRV, Lee TA. Economic modeling in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006;3:630-34. (Pubitemid 44411632)
55. Goossens L, Rutten-van Molken M, Nivens C. Is the EQ-5D responsive to recovery from a moderate COPD exacerbation? ISPOR 11th Annual European Conference. Athens, Greece, 2008.
56. Seemungal TA, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-13. (Pubitemid 30329036)
57. Brazier J, Tsuchiya A. Preference-based condition-specific measures of health: what happens to cross programme comparability? Health Econ 2010;19:125-9.